2BBBullish & Bearish
Incyte Corporation (INCY) trades on NASDAQ. It operates in the Health Care sector, Biotechnology industry. Its current 2BB score is 64 out of 100.
Incyte Corporation is an American multinational pharmaceutical company with headquarters in Wilmington, Delaware. The company currently operates manufacturing and R&D locations in North America, Europe, and Asia. Incyte Corporation currently develops and manufactures prescription biopharmaceutical medications in multiple therapeutic areas including oncology, inflammation, and autoimmunity.
Incyte Corporation’s current 2BB score is 64 out of 100, built from the signal categories below.
| Signal | Score | Reading |
|---|---|---|
| Activity | 74 | High |
| Momentum | 95 | Strongly Improving |
| Financial strength | 92 | Very Strong |
| Quality | 100 | Very Strong |
| Risk | 32 | Low |
| CEO | Hervé Hoppenot |
| Headquarters | Wilmington, Delaware, United States |
| Founded | 2002 |
| Employees | 2.84K |
| P/E ratio | 16.28 |
| 52-week range | $81.09 – $132.58 |
| Report date | EPS actual | EPS estimate | Revenue actual | Revenue estimate |
|---|---|---|---|---|
| 2027-02-08 | — | 1.9967 | — | $1.56B |
| 2026-10-26 | — | -3.4597 | — | $1.51B |
| 2026-07-28 | — | 2.105 | — | $1.46B |
| 2026-04-28 | 1.81 | 1.3984 | $1.27B | $1.24B |